X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Viropro cGMP Biomanufacturing Facility, Malaysia

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Asia, Projects

Alpha Biologics, a contract biomanufacturing service provider, commissioned a new cGMP biomanufacturing plant in April 2010. The plant, located at the Penang Biotech Park in Malaysia is dedicated to the production of mammalian cell secreted proteins.

The plant broke ground in June 2006 and was built at an investment of $18m between 2007 and 2009. It was constructed in compliance with the FDA and EMEA guidelines.

The design incorporates a flexible layout that was reviewed by the Centre of Drug Evaluation and Research (CDER) at the FDA and declared suitable for clinical studies and early market product development.

The facility has multiple rooms and functions that enable parallel working processes, thus reducing timelines and the eventual cost to the customer.

In the first quarter of 2010, Alpha Biologics was acquired by Viropro, a research and manufacturing service contractor based in Nevada. The acquisition was completed on 22 February 2010 for a consideration of $21m.

The facility is due to obtain accreditation under the Pharmaceutical Inspection Cooperation Scheme. The accreditation process is expected to commence in the next few months.

Facility

 

The plant spreads over an area of 5,000m² and accommodates upstream process development laboratories, cGMP manufacturing space and support areas.

“The design incorporates a flexible layout that was reviewed by the CDER.”

The manufacturing space includes process suites, isolation suites, two independent DSP suites and separate final filtration / viral removal suites. Class 10,000 (Grade C) process suites with Class 100,000 (Grade D) support areas are encircled by a return corridor, which provides visitors an inside view through the windows.

Waste material is disposed of via the return corridor, avoiding their crossover with clean items.

There are three isolation suites used for USP-cell banking and associated operations. These suites are equipped to develop master cell banks (MCB) and working cell banks (WCB), bioreactor seed or small scale product manufacturing for pre-clinical studies.

The bioreactor suite is equipped with seven bioreactors with capacities ranging from 10l to 500l (3 x 10l, 1 x 70l, 2 x 250l, 1 x 500l). The bioreactors can be operated in batch, fed-batch or perfusion mode – and the flexible design of the facility allows utilisation of bioreactors in different combinations in a closed system. There are two recovery suites for cell harvest clarification, with medium to large scale ultra filtration capabilities.

There are two purification suites for pre- and post-virus processing, equipped with chromatography and ultra-filtration skids and dedicated cold rooms. The final filtration / viral removal suites are installed with chromatography for final filtration and bulk aliquotting.

Upstream process development laboratories are located on the ground floor of the facility and are designed to allow the scale up of cell cultures in bioreactors of different capacity. Work in the upstream process laboratories is carried out with identical equipment to the cCMP manufacturing suites.

The bioreactor suite has three bioreactors of 10l, 70l and 250l capacities, all operable on batch, fed batch and perfusion mode. Purification equipment includes both small and large scale chromatography and ultra-filtration systems.

This use of identical equipment ensures smooth technical transfer to cGMP manufacture, with a few operational changes and cleaning validation to reduce normal timelines for process development and cGMP manufacture. This, in turn, results in major cost savings for clients.

“The bioreactor suite has three bioreactors of 10l, 70l and 250l capacities.”

The facility also includes microbiology and quality control laboratories for environmental testing, analytical laboratories for in-process assays and a buffer preparation unit with 50l, 120l, 250l and 1000l preparation vessels.

There is also a cell bank and product storage zone for -20°C, -80°C and liquid and vapour phase nitrogen storage.

Additional equipment in this part of the plant includes process washing machines, sterilising autoclaves and CIP station.

Production

 

The facility is dedicated to the production of proteins secreted from mammalian cell cultures, including monoclonal antibodies and recombinant proteins. Hybridoma, CHO and NSO cell lines are the most common cell types used.

Prior to cGMP manufacturing, the facility develops cell lines and master and manufacturing working cell banks. The facility also produces supernatants, membrane fractions or other product options.

The facility has been designed to combine bioreactors with perfusion technology whenever required, to increase production capacity by 20 fold. This combination of stirred tank processes and perfusion enables ultra-efficient production of secreted protein for pre-clinical or clinical trial studies or early market use.

Tags: Asia Pacific
Previous Post

Aventis Enoxaparin Sodium Manufacturing Plant, Singapore

Next Post

AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia, United Kingdom

Related Posts

Indian Pharmaceutical Industry In 2021 And The Road Ahead
Asia

Indian Pharmaceutical Industry In 2021 And The Road Ahead

24th January 2022
Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison
Asia

India crosses historic one billion COVID-19 vaccine milestone

26th October 2021
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
Asia

UAE approves use of Sinopharm vaccine for children aged between 3 and 17 years

5th August 2021
Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market
Asia

Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market

17th May 2021
India authorises DRDO's oxygen dependence-lowering drug for Covid-19
Asia

India authorises DRDO’s oxygen dependence-lowering drug for Covid-19

11th May 2021
New dates for MEDICAL FAIR THAILAND with move to 2022
Asia

New dates for MEDICAL FAIR THAILAND with move to 2022

30th April 2021
Next Post

AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia, United Kingdom

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In